- IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed -
Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of PresidentGilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities
We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.
- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway
- Conference Call Scheduled for Today at 8:30 A.M. ET
- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -
- Company Continues to Advance Gene Therapy Portfolio -
Please subscribe to receive our latest news